NASDAQ · ALLK
Allakos Inc.
$0.33+$0.00 (+0.22%)
Allakos Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.9% below the high.
Loading market information…
NASDAQ · LSB · USD
Stock price, earnings
Quote as of Sep 19, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow LakeShore Biopharma Co., Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $176.27M |
| Q3 2023 | Mar 31, 2023 | -$17.98 | $106.12M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.33+$0.00 (+0.22%)
Allakos Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.9% below the high.
$6.49+$0.01 (+0.15%)
Freeline Therapeutics Holdings plc’s quoted price sits in the upper half of its reported 52-week range, 25.79% below the high.
$8.50+$0.01 (+0.12%)
Liminal BioSciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$4.30-$0.14 (-3.15%)
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$1.73-$0.17 (-8.73%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.5% below the high.
$1.35$0.00 (0.0%)
Gemini Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.53% below the high.
$0.66$0.00 (0.0%)
Invacare Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.92% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
